11 results about "Programmed death 1" patented technology

This disclosure provides methods for treating tumors, reducing tumor severity, inhibiting tumor growth, or inducing tumor necrosis, wherein the methods include: selecting a patient with cancer (e.g., liver cancer, lung cancer, or head and neck cancer) in need of treatment and administering neoadjuvant therapy to the patient in a combination of a therapeutically effective amount of a programmed death 1 (PD-1) inhibitor (e.g., cimiprimab or its bioequivalent) and radiation therapy (e.g., SBRT) or an anti-LAG-3 antibody (e.g., fenpromab), followed by surgical resection and optionally administration of a programmed death 1 (PD-1) inhibitor (e.g., cimiprimab or its bioequivalent) as postoperative adjuvant therapy. In some embodiments, the cancer is liver cancer, such as hepatocellular carcinoma (HCC).

This disclosure provides methods for treating endometrial cancer, reducing its severity, or inhibiting its growth. The methods of this disclosure comprise administering to a subject in need a single therapeutically effective amount of a bispecific antibody that specifically binds to mucin 16 (MUC16) and CD3, or administering said bispecific antibody in combination with a therapeutically effective amount of an antibody specifically binding to the programmed death 1 (PD-1) receptor or an antigen-binding fragment thereof.

Provided herein are recombinant antibodies, antigen-binding fragments, and fusion proteins thereof useful for binding to and inhibiting programmed death 1 (PD-1), nucleic acid molecules encoding the same and therapeutic compositions thereof, as well as methods of using such antibodies, including the methods for enhancing T cell and NK cell function to increase cell and cytokine mediated immunity and methods of treatment of various immune dysfunction related disorders including cancer and infectious diseases.

Provided herein are recombinant antibodies, antigen-binding fragments, and fusion proteins thereof useful for binding to and inhibiting programmed death 1 (PD-1), nucleic acid molecules encoding the same and therapeutic compositions thereof, as well as methods of using such antibodies, including the methods for enhancing T cell and NK cell function to increase cell and cytokine mediated immunity and methods of treatment of various immune dysfunction related disorders including cancer and infectious diseases.

The disclosure relates to methods for treating or inhibiting the growth of a tumor, wherein the methods include selecting a subject with a skin cancer and intralesionally administering to the tumor of the subject in need thereof a therapeutically effective amount of a programmed death 1 (PD-1) inhibitor (e.g., an antibody or antigen-binding fragment thereof that specifically binds PD-1, PD-L1, and / or PD-L2). In certain embodiments, the skin cancer is cutaneous squamous cell carcinoma. In certain embodiments, the PD-1 inhibitor is administered into multiple locations of the tumor lesion.

The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a VEGFR inhibitor, and the use of the combination therapies for the treatment of cancer, and in particular for treating cancers that express PD-L1.

The present disclosure describes a combination therapy comprising an antagonist of Programmed Death 1 receptor (PD-1), a lenvatinib or a pharmaceutically acceptable salt thereof, and (6S,9aS)-N- benzyl-8-({6-[3-(4-ethylpiperazin-l-yl)azetidin-l-yl]pyridin-2- yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-l- yl)hexahydro-2H-pyrazino[2,l-c][l,2,4]triazine-l(6H)-carboxamide (E7386) or a pharmaceutically acceptable salt thereof, and the use of the combination therapies for the treatment of a cancer.

This invention relates to combination therapies comprising a Programmed Death 1 receptor (PD-1) pathway inhibitor, and a Leukocyte Immunoglobulin Like Receptor B (LILRB) signaling inhibitor, and the use of the combination therapies for the treatment of cancer. The invention also relates to the treatment of cancer patients who are refractory to monotherapy with a PD-1 pathway inhibitor.

The present invention provides methods for treating, reducing the severity, or inhibiting the growth of cancer (e.g., lung cancer). The methods of the present invention comprise administering a therapeutically effective amount of a programmed death 1 (PD-1) antagonist (e.g., an anti-PD-1 antibody), to a subject with lung cancer wherein the cancer tissue expresses PD-L1.

The present disclosure describes a combination therapy comprising an antagonist of Programmed Death 1 receptor (PD-1), a lenvatinib or a pharmaceutically acceptable salt thereof, and (6S,9aS)-N-benzyl-8-({6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2H-pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxamide (E7386) or a pharmaceutically acceptable salt thereof, —and the use of the combination therapies for the treatment of a cancer.

The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a VEGFR inhibitor, and the use of the combination therapies for the treatment of cancer, and in particular for treating cancers that express PD-L1.